Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced that it will participate in the
American Society for Cataract and Refractive Surgery (ASCRS) Symposium &
Congress, to be held in Los Angeles, California, on May 5 through May 9,
2017. The ASCRS is one of the most dynamic cataract and refractive
events of the year and attracts experts from all over the globe to
present on the newest scientific research and trends in cataract and
refractive surgery. Dr. Tae-Young Chung, Associate Professor at the
Department of Ophthalmology at Samsung Medical Center in South Korea,
will conduct presentations on outcomes with the Presbia Flexivue
Microlens™ at the meeting.
The Ophthalmology Innovation Summit (OIS), where groundbreaking
technologies are discussed, takes place on May 4, 2017, just prior to
the ASCRS, in Los Angeles as well. Prof. Gerd Auffarth, MD, PHD from the
University of Heidelberg will present on his experience with the Presbia
Flexivue Microlens at this meeting.
Presbia clinical and business personnel will be available for one-on-one
meetings at the Congress. For more information please visit booth #2459.
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170503006852/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media